CLAIMS

1. A water-stable film, comprising:

one or more cellulosic polymers present in an amount from about 10 to about 50% of the film's dry weight,

polyvinyl acetate present in an amount from about 8 to about 25% of the film's dry weight; and

particles selected from silicon oxide, molybdenum oxide, aluminum oxide, titanium oxide, zirconium oxide and zinc oxide, wherein the particles are present at a concentration of greater than about 25% of the film's dry weight.

2. The film of claim 1, wherein the polyvinyl acetate is present at a concentration of from about 10 to about 20% of the film's dry weight.

3. The film of any one of claims 1 to 2, wherein the one or more cellulosic polymers are present at a concentration of from about 15 to about 30%, of the film's dry weight.

4. The film of any one of claims 1 to 3, wherein the one or more cellulosic polymers are present at a concentration of from about 18 to about 22%, of the film's dry weight.

5. The film of any one of claims 1 to 4, wherein the particles are present at a concentration of from about 45 to about 55% of the film's dry weight.

6. The film of any one of claims 1 to 5, wherein the particles are zinc oxide particles.

7. The film of any one of claims 1 to 6, wherein at least one of the one or more cellulosic polymers is hydroxypropyl methyl cellulose.

8. An aqueous oral care composition comprising:
the film of any one of claims 1 to 7; and
an orally acceptable aqueous carrier;
wherein the film is present at a concentration of from about 0.1 to about 2%, by weight of the composition.

9. The composition of claim 8, wherein the composition has a G' to G'' ratio of greater than or equal to 1.

10. The composition of claim 8 or 9, wherein the film is suspended in the aqueous carrier.

11. The composition of any one of claims 8 to 10, wherein the presence of the film does not increase the optical density at 610 nm by more that 0.01 after 20 hours compared to the optical density at 610 nm of the composition free of the film after 20 hours.

12. The composition of any one of claims 8 to 10, wherein the presence of the film does not increase the optical density at 610 nm by more that .002 after 20 hours compared to the optical density at 610 nm of the composition free of the film after 20 hours.

13. Use of the composition of any one of claims 8 to 12 in the manufacture of a medicament for reducing the amount of volatile sulfur compounds in the oral cavity of a subject in need thereof by at least 25%.

14. Use of the composition of any one of claims 8 to 12 in the manufacture of a medicament for treating or preventing gingivitis, periodontitis or haltitosis.

15. A composition according to any one of claims 8 to 13, for use in treatment or prevention of gingivitis, periodontitis or haltitosis.

REPLACEMENT SHEET Attorney Docket No.: 9091-00-WO-OC

CLAIMS

1. A water-stable film, comprising:

one or more cellulosic polymers present in an amount from about 10 to about 50% of the film's dry weight,

polyvinyl acetate present in an amount from about 8 to about 25% of the film's dry weight; and

particles selected from silicon oxide, molybdenum oxide, aluminum oxide, titanium oxide, zirconium oxide and zinc oxide, wherein the particles are present at a concentration of greater than about 25% of the film's dry weight.

2. The film of claim 1, wherein the polyvinyl acetate is present at a concentration of from about 10 to about 20% of the film's dry weight.

3. The film of claim 1 or claim 2, wherein the polyvinyl acetate is present at a concentration of about 18%, of the film's dry weight.

4. The film of any one of claims 1 to 3, wherein the one or more cellulosic polymers are present at a concentration of from about 15 to about 30%, of the film's dry weight.

5. The film of any one of claims 1 to 4, wherein the one or more cellulosic polymers are present at a concentration of from about 18 to about 22%, of the film's dry weight.

6. The film of any one of claims 1 to 5, wherein the particles are present at a concentration of from about 30 to about 60% of the film's dry weight.

REPLACEMENT SHEET Attorney Docket No.: 9091-00-WO-OC

7. The film of any one of claims 1 to 6, wherein the particles are present at a concentration of from about 45 to about 55% of the film's dry weight.

8. The film of any one of claims 1 to 7, wherein the particles are zinc oxide particles.

9. The film of any one of claims 1 to 8, wherein at least one of the one or more cellulosic polymers is hydroxypropyl methyl cellulose.

10. An aqueous oral care composition comprising:
the film of any one of claims 1 to 9; and
an orally acceptable aqueous carrier.

11. The composition of claim 10, wherein the composition has a G' to G'' ratio of greater than or equal to 1.

12. The composition of claim 10 or 11, wherein the film is suspended in the aqueous carrier.

13. The composition of any one of claims 10 to 12, wherein the presence of the film does not increase the optical density at 610 nm by more that 0.01 after 20 hours compared to the optical density at 610 nm of the composition free of the film after 20 hours.

14. The composition of any one of claims 10 to 12, wherein the presence of the film does not increase the optical density at 610 nm by more that .002 after 20 hours compared to the optical density at 610 nm of the composition free of the film after 20 hours.

.2012 11:45:49 - 22.10.2012 11:50:16. This page 12 of 1 AMENDED SHEET 2012 11:49:19
at the EPO on Oct 22, 2012 11:50:16. Page 12 of 15

15. The composition of any one of claims 10 to 14, wherein the film is present at a concentration of from about 0.1 to about 2%, by weight of the composition.

16. The composition of any one of claims 10 to 15, wherein the composition reduces the amount of volatile sulfur compounds in the oral cavity by at least 25%.

17. A method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a subject in need thereof, with the composition of any one of claims 10 to 16.

18. The method of claim 17, wherein the disease or condition of the oral cavity is selected from gingivitis; periodontitis; and halitosis.

19. A composition according to any one of claims 10 to 16, for use in treatment or prevention of a disease or condition of the oral cavity.

20. The composition of claim 19, wherein the disease or condition of the oral cavity is selected from gingivitis, periodontitis, and halitosis.

10.2012 11:45:49 - 22.10.2012 11:50:16. This page 13 of 1 AMENDED SHEET 2012 11:49:31
ed at the EPO on Oct 22, 2012 11:50:16. Page 13 of 15